Combined modality therapy for esophageal cancer

Charles Blanke, H. Choy, S. D. Leach

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Esophageal cancer remains one of the deadliest gastrointestinal malignancies. Single modality therapy for esophageal cancer usually consists of surgery or radiation therapy. Despite wide ranges in survival rates reported for the two modalities, recent analyses suggest that each offers a 5-year survival of approximately 6%. Surgery plus radiation therapy has been evaluated in a number of studies; results have been equivocal, with response and survival rates similar to those of single modality therapy. Some studies evaluating chemotherapy followed by surgery have resulted in improved partial response rates (17%-57%), with median survival similar to single modality treatment. In two randomized trials, the combination of chemotherapy and surgery was not superior to single modality therapy in terms of response and survival. Because the results of these trials are not in agreement, analysis of results from the recently completed Intergroup study, which compared surgery alone to surgery plus cisplatin/fluorouracil, are eagerly awaited. Studies of radiation plus chemotherapy have shown decreases in both local and distant disease recurrence. Trimodality therapy (surgery plus radiation plus chemotherapy) with a variety of schedules also has been explored. Results suggest that surgery may not be of added benefit to radiation plus chemotherapy; however, a direct comparison of trimodality therapy versus chemotherapy plus radiation has not been performed. Numerous questions remain regarding the most efficacious treatment of nonmetastatic esophageal cancer, and further study is required to identify the ideal treatment.

Original languageEnglish (US)
Pages (from-to)15-23
Number of pages9
JournalSeminars in Radiation Oncology
Volume7
Issue number3 SUPPL. 2
StatePublished - 1997

Fingerprint

Combined Modality Therapy
Esophageal Neoplasms
surgery
therapy
chemotherapy
cancer
Drug Therapy
Radiation
radiation
Therapeutics
radiation therapy
Radiotherapy
schedules
Combination Drug Therapy
Fluorouracil
Cisplatin
Appointments and Schedules
Recurrence

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Radiation

Cite this

Blanke, C., Choy, H., & Leach, S. D. (1997). Combined modality therapy for esophageal cancer. Seminars in Radiation Oncology, 7(3 SUPPL. 2), 15-23.

Combined modality therapy for esophageal cancer. / Blanke, Charles; Choy, H.; Leach, S. D.

In: Seminars in Radiation Oncology, Vol. 7, No. 3 SUPPL. 2, 1997, p. 15-23.

Research output: Contribution to journalArticle

Blanke, C, Choy, H & Leach, SD 1997, 'Combined modality therapy for esophageal cancer', Seminars in Radiation Oncology, vol. 7, no. 3 SUPPL. 2, pp. 15-23.
Blanke, Charles ; Choy, H. ; Leach, S. D. / Combined modality therapy for esophageal cancer. In: Seminars in Radiation Oncology. 1997 ; Vol. 7, No. 3 SUPPL. 2. pp. 15-23.
@article{3c4f1524d0eb4c1d94fc892be1e0dcc7,
title = "Combined modality therapy for esophageal cancer",
abstract = "Esophageal cancer remains one of the deadliest gastrointestinal malignancies. Single modality therapy for esophageal cancer usually consists of surgery or radiation therapy. Despite wide ranges in survival rates reported for the two modalities, recent analyses suggest that each offers a 5-year survival of approximately 6{\%}. Surgery plus radiation therapy has been evaluated in a number of studies; results have been equivocal, with response and survival rates similar to those of single modality therapy. Some studies evaluating chemotherapy followed by surgery have resulted in improved partial response rates (17{\%}-57{\%}), with median survival similar to single modality treatment. In two randomized trials, the combination of chemotherapy and surgery was not superior to single modality therapy in terms of response and survival. Because the results of these trials are not in agreement, analysis of results from the recently completed Intergroup study, which compared surgery alone to surgery plus cisplatin/fluorouracil, are eagerly awaited. Studies of radiation plus chemotherapy have shown decreases in both local and distant disease recurrence. Trimodality therapy (surgery plus radiation plus chemotherapy) with a variety of schedules also has been explored. Results suggest that surgery may not be of added benefit to radiation plus chemotherapy; however, a direct comparison of trimodality therapy versus chemotherapy plus radiation has not been performed. Numerous questions remain regarding the most efficacious treatment of nonmetastatic esophageal cancer, and further study is required to identify the ideal treatment.",
author = "Charles Blanke and H. Choy and Leach, {S. D.}",
year = "1997",
language = "English (US)",
volume = "7",
pages = "15--23",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 2",

}

TY - JOUR

T1 - Combined modality therapy for esophageal cancer

AU - Blanke, Charles

AU - Choy, H.

AU - Leach, S. D.

PY - 1997

Y1 - 1997

N2 - Esophageal cancer remains one of the deadliest gastrointestinal malignancies. Single modality therapy for esophageal cancer usually consists of surgery or radiation therapy. Despite wide ranges in survival rates reported for the two modalities, recent analyses suggest that each offers a 5-year survival of approximately 6%. Surgery plus radiation therapy has been evaluated in a number of studies; results have been equivocal, with response and survival rates similar to those of single modality therapy. Some studies evaluating chemotherapy followed by surgery have resulted in improved partial response rates (17%-57%), with median survival similar to single modality treatment. In two randomized trials, the combination of chemotherapy and surgery was not superior to single modality therapy in terms of response and survival. Because the results of these trials are not in agreement, analysis of results from the recently completed Intergroup study, which compared surgery alone to surgery plus cisplatin/fluorouracil, are eagerly awaited. Studies of radiation plus chemotherapy have shown decreases in both local and distant disease recurrence. Trimodality therapy (surgery plus radiation plus chemotherapy) with a variety of schedules also has been explored. Results suggest that surgery may not be of added benefit to radiation plus chemotherapy; however, a direct comparison of trimodality therapy versus chemotherapy plus radiation has not been performed. Numerous questions remain regarding the most efficacious treatment of nonmetastatic esophageal cancer, and further study is required to identify the ideal treatment.

AB - Esophageal cancer remains one of the deadliest gastrointestinal malignancies. Single modality therapy for esophageal cancer usually consists of surgery or radiation therapy. Despite wide ranges in survival rates reported for the two modalities, recent analyses suggest that each offers a 5-year survival of approximately 6%. Surgery plus radiation therapy has been evaluated in a number of studies; results have been equivocal, with response and survival rates similar to those of single modality therapy. Some studies evaluating chemotherapy followed by surgery have resulted in improved partial response rates (17%-57%), with median survival similar to single modality treatment. In two randomized trials, the combination of chemotherapy and surgery was not superior to single modality therapy in terms of response and survival. Because the results of these trials are not in agreement, analysis of results from the recently completed Intergroup study, which compared surgery alone to surgery plus cisplatin/fluorouracil, are eagerly awaited. Studies of radiation plus chemotherapy have shown decreases in both local and distant disease recurrence. Trimodality therapy (surgery plus radiation plus chemotherapy) with a variety of schedules also has been explored. Results suggest that surgery may not be of added benefit to radiation plus chemotherapy; however, a direct comparison of trimodality therapy versus chemotherapy plus radiation has not been performed. Numerous questions remain regarding the most efficacious treatment of nonmetastatic esophageal cancer, and further study is required to identify the ideal treatment.

UR - http://www.scopus.com/inward/record.url?scp=0030747988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030747988&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 15

EP - 23

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 3 SUPPL. 2

ER -